Catalyst CEO Patrick McEnany declined to comment except to say that the company would be responding to Senator Sanders request in a timely manner NegativeNEW YORK Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease which had long been available to patients for free will cost more than per year including rebates to insurers and other discounts